News

Pfizer has selected a once-daily formulation of danuglipron, an oral GLP-1 receptor agonist, based on encouraging results from an...

Pluristyx, a renowned cellular therapy developer, has partnered with Humacyte, a biotechnology company specializing in bioengineered human tissue. This...

Obsidian Therapeutics has secured Fast Track Designation from the FDA for OBX-115, an engineered T-cell therapy targeting metastatic or...

SEQSTER and Antidote have revolutionized patient matching and clinical research efficiency. SEQSTER’s patient-centric healthcare platform provides a comprehensive view...

The Food and Drug Administration (FDA) has approved updates to Susvimo, an eye implant treatment for wet age-related macular...

Genexine, a Korean biopharmaceutical company, has merged with EPD Biotherapeutics, specializing in targeted protein degradation (TPD) technology. This merger...

Calidi Biotherapeutics has authorized a one-for-ten reverse stock split, effective July 15, 2024. The split will be applied to...

ACTICOR BIOTECH, a clinical-stage pharmaceutical company, reports its voting rights and shares as of May 31, 2024. The company...

Merck and Orion Corporation have converted their co-development and co-commercialization agreement for opevesostat into an exclusive global license for...

N-Power Medicine has secured initial funding in a Series B round, boosting its total funding to $72 million. Led...